MAM
ZVRA icon

Mystic Asset Management’s Zevra Therapeutics ZVRA Stock Holding History

Mystic Asset Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.05M Sell
352,110
-9,173
-3% -$102K 1.08% 22
2026
Q1 		$3.37M Buy
361,283
+14,756
+4% +$133K 0.78% 36
2025
Q4 		$3.1M Sell
346,527
-125
-0% -$1.18K 0.7% 37
2025
Q3 		$3.3M Hold
346,652
– – 0.74% 35
2025
Q2 		$3.05M Buy
346,652
+7,750
+2% +$62.9K 0.74% 38
2025
Q1 		$2.54M Buy
338,902
+25,555
+8% +$203K 0.67% 42
2024
Q4 		$2.61M Buy
313,347
+5,900
+2% +$50.4K 0.7% 38
2024
Q3 		$2.13M Buy
307,447
+9,500
+3% +$64.5K 0.81% 35
2024
Q2 		$1.46M Buy
297,947
+31,650
+12% +$150K 0.59% 53
2024
Q1 		$1.54M Buy
266,297
+35,514
+15% +$218K 0.64% 50
2023
Q4 		$1.51M Buy
230,783
+27,500
+14% +$129K 0.72% 43
2023
Q3 		$980K Buy
203,283
+14,750
+8% +$73.6K 0.55% 59
2023
Q2 		$962K Buy
188,533
+11,000
+6% +$59.3K 0.52% 68
2023
Q1 		$976K Buy
177,533
+1,650
+0.9% +$8.73K 0.54% 66
2022
Q4 		$807K Buy
175,883
+11,000
+7% +$55.9K 0.46% 75
2022
Q3 		$1.03M Buy
164,883
+7,350
+5% +$41.6K 0.66% 56
2022
Q2 		$702K Buy
157,533
+53,452
+51% +$244K 0.43% 79
2022
Q1 		$523K Buy
104,081
+32,100
+45% +$204K 0.28% 101
2021
Q4 		$626K Buy
+71,981
New +$642K 0.3% 93

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mystic Asset Management's ZVRA Position: Q2 2026 in Review

Mystic Asset Management reduced its Zevra Therapeutics (ZVRA) stake by 2.5% in Q2 2026, selling an estimated $102K and leaving 352,110 shares worth $5.05M. The position accounts for 1.08% of the portfolio, ranked #22.

Mystic Asset Management first reported a position in ZVRA in Q4 2021 and has held it in 19 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Mystic Asset Management held 352,110 shares of Zevra Therapeutics worth $5.05M as of Q2 2026.
  • Mystic Asset Management sold 9,173 Zevra Therapeutics shares in Q2 2026, an estimated $102K.
  • Zevra Therapeutics made up 1.08% of Mystic Asset Management's portfolio in Q2 2026, its #22 holding.
  • Mystic Asset Management first reported a position in Zevra Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Mystic Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.